AGENTIX Corp.

We will strive to deliver innovative and meaning therapies to our patients, by innovating the frontiers of metabolic disease.

AGENTIX and RTI International Announce Worldwide Exclusive License and Services Agreement
New York, New York--(Newsfile Corp. - December 21, 2021) - AGENTIX Corporation (OTC Pink: AGTX), a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases, announced today it has entered into an amendment to a Patent and Know-How License Agreement between the parties, dated October 22, 2021, a worldwide exclusive license and services agreement with Research Triangle Institute, dba RTI International ("RTI"), a nonprofit research institute, concerning the commercialization of certain RTI...
2021-12-21 5:00 AM EST
AGENTIX Corporation and the National Health Research Institutions Announce Worldwide Exclusive License Agreements
New York, New York--(Newsfile Corp. - September 8, 2021) - AGENTIX Corp. (OTC Pink: AGTX), a pharmaceutical company focused on developing innovative therapeutic treatments targeting the endocannabinoid system (ECS) for the treatment of metabolic diseases, announced today it had entered into a worldwide exclusive license agreement and technology transfer agreement with the National Health Research Institutes ("NHRI") of Taiwan ROC, a nonprofit research institute, concerning the development and commercialization of DBPR211, an innovative new chemical entity with pre-clinical evidence demonstrating...
2021-09-08 8:00 AM EDT